Home › Non-Small Cell Lung Cancer › California › Los Angeles
Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Los Angeles, CA
Isang pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Los Angeles. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- Start Los Angeles /ID# 284999, Los Angeles
- Valkyrie Clinical Trials /ID# 271322, Los Angeles
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Nagre-recruitPhase 3
- Cedars-Sinai Medical Center, Los Angeles
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- The Angeles Clinic and Research Institute (Melanoma), Los Angeles
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Nagre-recruitPhase 2
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Nagre-recruitPhase 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Nagre-recruitPhase 3
- USC Norris Comprehensive Cancer Center ( Site 0205), Los Angeles
- UCLA Jonsson Comprehensive Cancer Center ( Site 0135), Los Angeles
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Nagre-recruitPhase 3
- Cedars-Sinai Medical Center, Los Angeles
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Nagre-recruitPhase 1
- University of California Los Angeles, Los Angeles
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Nagre-recruitPhase 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Nagre-recruitPhase 2
- START LA, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Nagre-recruitPhase 3
- Local Institution - 0422, Los Angeles
A Study of PHN-012 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1
- PHN-012-001 Site, Los Angeles
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Nagre-recruitPhase 1
- Research Site, Los Angeles
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Nagre-recruitPhase 3
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0033), Los Angeles
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Oncura Health - Good Samaritan, Los Angeles
- California Research Institute, Los Angeles
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- USC Norris Comprehensive Cancer Center, Los Angeles
- Cedars Sinai Medical Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Nagre-recruitPhase 1
- Research Site, Los Angeles
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Nagre-recruitPhase 1/2
- START Los Angeles, LLC, Los Angeles
- LACN Century City, Los Angeles
- Valkyrie Clinical Trials (Additional Site Pharmacy Storage Suite), Los Angeles
- at 2 pa
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Nagre-recruitPhase 1/2
- University of Southern California, Los Angeles
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Nagre-recruitPhase 2
- Research Site, Los Angeles
Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD
Nagre-recruitObservasyonal na pag-aaral
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Nagre-recruitPhase 1/2
- START Los Angeles, Los Angeles
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Nagre-recruitPhase 3
- Clinical Study Site, Los Angeles
- Clinical Study Site, Los Angeles
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Nagre-recruitPhase 3
- UCLA Health - Santa Monica Cancer Care, Los Angeles
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Nagre-recruitPhase 1/2
- The Angeles clinic - A cedars SINAI AFFILIATE, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Nagre-recruitPhase 1/2
- Valkyrie Clinical Trials, Los Angeles
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Nagre-recruitPhase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- California Research Institute, Los Angeles
- Los Angeles Cancer Network (LACN), Los Angeles
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Nagre-recruitPhase 1
- Site 105 - START Los Angeles, Los Angeles
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Nagre-recruitPhase 1/2
- UCLA Health Bowyer Oncology Center, Los Angeles
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Nagre-recruitPhase 1
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Cedars-Sinai Medical Center, Los Angeles
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- UCLA Oncology Center, Los Angeles
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Nagre-recruitPhase 3
- Research Site, Los Angeles
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- University of Southern California, Los Angeles
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Nagre-recruitPhase 1
- The Angeles Clinic, Los Angeles
- UCLA, Los Angeles
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Nagre-recruitPhase 3
- USC/Norris Comprehensive Cancer Center, Los Angeles
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Research Site, Los Angeles
- Research Site, Los Angeles
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Nagre-recruitPhase 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
SMP-3124LP in Adults With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- The Angeles Clinic and Research Institute, Los Angeles
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Nagre-recruitPhase 1
- Cedars-Sinai Cancer at The Angeles Clinic and Research Institute, Los Angeles
- Cedars-Sinai Cancer at SOCC, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 1/2
- UCLA Hematology Oncology - Main Site, Los Angeles
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- UCLA - Hematology/Oncology Clinical Research Unit, Los Angeles
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- University of California Los Angeles Medical Center, Los Angeles
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Nagre-recruitPhase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- University of California Los Angeles, Los Angeles
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Nagre-recruitPhase 1
- University of California LA, Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Nagre-recruitPhase 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Nagre-recruitPhase 1/2
- Cedars Sinai, Los Angeles
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Nagre-recruitPhase 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Nagre-recruitPhase 2
- Valkyrie Clinical Trials, Inc, Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Gilteritinib for the Treatment of ALK NSCLC
Nagre-recruitPhase 1
- Cedars-Sinai Medical Center, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Nagre-recruitPhase 1
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Study of XB010 in Subjects With Solid Tumors
Nagre-recruitPhase 1
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Nagre-recruitPhase 1/2
- UCLA Medical Center, Los Angeles
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Nagre-recruitPhase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Nagre-recruitPhase 1
- Start Lacn, Los Angeles
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Nagre-recruitPhase 1
- University of Southern California, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Cedars-Sinai Medical Center, Los Angeles
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Nagre-recruitPhase 1
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Nagre-recruitPhase 3
- UCLA, Los Angeles
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Cedars-Sinai Medical Center, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Nagre-recruit
- Oncology Institute for Hope and Innovation, Los Angeles
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Nagre-recruitPhase 1/2
- Cedars-Sinai Medical Center, Los Angeles
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Nagre-recruitPhase 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 2
- Cedars Sinai Medical Center, Los Angeles
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Nagre-recruitPhase 1/2
- University of California Los Angeles, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
Nagre-recruitPhase 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- USC Norris Comprehensive Cancer Center, Los Angeles
Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
Nagre-recruitObservasyonal na pag-aaral
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
GEMINI-NSCLC: NSCLC Biomarker Study
Nagre-recruitObservasyonal na pag-aaral
- UCLA, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Nagre-recruitPhase 1/2
- University of Southern California, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Nagre-recruitPhase 1/2
- UCLA Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
Nagre-recruitPhase 1
- University of Southern California, Los Angeles
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Nagre-recruitPhase 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod
- Houston, TX145 pag-aaral
- New York City, NY121 pag-aaral
- Arlington, VA104 pag-aaral
- Nashville, TN97 pag-aaral
- Boston, MA90 pag-aaral
- St. Louis, MO73 pag-aaral
- Chicago, IL61 pag-aaral
- Baltimore, MD60 pag-aaral
- San Antonio, TX59 pag-aaral
- Columbus, OH57 pag-aaral
- Washington, DC55 pag-aaral
- Seattle, WA53 pag-aaral
Iba pang pag-aaral sa Los Angeles
- Kanser (lahat ng uri)74 pag-aaral
- Kanser sa Suso73 pag-aaral
- Kanser sa Prostate61 pag-aaral
- Colorectal Cancer59 pag-aaral
- Metastatic Cancer57 pag-aaral
- Kanser sa Ovary50 pag-aaral
- Kanser sa Baga45 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg42 pag-aaral
- Kanser sa Pancreas35 pag-aaral
- Kanser ng Endometrium34 pag-aaral
- Melanoma34 pag-aaral
- Triple-Negative Breast Cancer27 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.